LBLucas Baudouin

Lucas Baudouin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Lucas Baudouin has a total of 61 co-authors. Here are the top co-authors by number of shared publications:

  • Bassem A. Hassan

    Institut du Cerveau-Paris Brain Institute (ICM), Sorbonne Université, Inserm, CNRS, Hôpital Pitié-Salpêtrière, Paris, France

    3 shared publications
  • Carlos Parras

    Paris Brain Institute, Sorbonne Université, Inserm U1127, CNRS UMR 7225, Hôpital Pitié-Salpêtrière, Paris, France

    3 shared publications
  • Corentine Marie

    Paris Brain Institute, Sorbonne Université, Inserm U1127, CNRS UMR 7225, Hôpital Pitié-Salpêtrière, Paris, France

    3 shared publications
  • Corinne Bachelin

    3 shared publications
  • Jean-Baptiste Huré

    Paris Brain Institute, Sorbonne Université, Inserm U1127, CNRS UMR 7225, Hôpital Pitié-Salpêtrière, Paris, France

    3 shared publications
  • Julie-Anne Chemelle

    Équipe ECMO, Laboratoire de Biologie Tissulaire et d’Ingénierie (LBTI), UMR5305, Lyon, France

    3 shared publications

Latest Publications

  • Open Access

    Experimental Framework to Investigate Glioma in Organotypic Human Cortex

    by Lotte R. Woltheus, Lucas Baudouin, Marike van Lingen, Niels Verburg, Sander Idema, Myron G. Best, Phillip de Witt Hamer, David Noske, Linda Douw, Dorien Maas

    Background: Gliomas are primary brain tumors that integrate into the surrounding brain via neuron-glioma synapses and disrupt normal neuronal functioning. Recent work links tumor-brain connectivity to clinical measures such as patients’ functional status. However, few experimental systems allow the visualization of tumor and resident brain cell architecture together in human tissue at the scale needed to connect cellular organization to clinical outcomes. To address this gap, we developed an experimental framework for investigating the neuron-glioma network in organotypic human cortex from glioma patients, designed to support future correlation of cellular architecture to clinical outcomes such as functional status and survival. Methods: Brain tissue samples containing cortex from seven glioma patients were collected during tumor resection and cultured for seven days as organotypic slices. We established several multiplexed immunohistochemistry panels to stain for glioma cells, various types of resident brain cells including neurons and cells from the oligodendrocyte lineage, as well as axonal networks and myelination patterns. Results: We demonstrated the presence of tumor cells in all samples using SOX2, a tumor cell marker. NeuN+ neuronal cells were also successfully identified, as were cells from the oligodendrocyte lineage using SOX10 (pan-lineage marker), BCAS1 (pre-myelinating oligodendrocyte marker), and ASPA (mature oligodendrocyte marker). The neuronal network and myelin were successfully visualized using MAP2 (neurons and dendrites), SMI312 (axons), and PLP1 (myelin). Conclusions: High-quality visualization of tumor cells, resident brain cells and the (myelinated) neuronal network in organotypic human cortex from glioma patients is possible after seven days of culturing. Future studies could further optimize culture conditions and should study stability of all cellular components in longer term slice cultures. Preliminary analyses indicate that cellular measures derived from human organotypic slices can be linked to patients’ functional status, demonstrating the capacity to generate data suitable for large-scale investigation of the effects of glioma-brain network architecture on clinical outcomes.

  • Fonctions de PAK1 dans la régulation du cytosquelette d’actine : implication dans la myélinisation du système nerveux central

    by Lucas Baudouin

    Dans le système nerveux central (SNC), la formation de la myéline par les oligodendrocytes (OL) est orchestrée par la dynamique du cytosquelette d’actine. L’extension et l’enroulement des prolongements des OL autour de l’axone nécessitent une régulation du processus de polymérisation-dépolymérisation de l’actine ; essentielle pour la myélinisation. Cependant, les mécanismes moléculaires déclenchant ce processus restent inconnus. Nous avons identifié la protéine p21-activated kinase 1 (PAK1) comme candidate potentielle de cette transition de l’état de l’actine. Au demeurant, son rôle dans la myélinisation du SNC des mammifères reste inconnu. Nous avons découvert que la principale forme de PAK1 présente dans les OL est inactive (non phosphorylée). Nous avons également démontré que l’inhibition précoce de PAK1 dans les OL augmente la dépolymérisation de l’actine et la formation des membranes des OL in vitro, et stimule la myélinisation dans des tranches de cervelet. Inversement, l’activation constitutive de PAK1 restreint la dépolymérisation de l’actine et par conséquent la formation des membranes des OL. En parallèle, nous avons mis en évidence que la perte de fonction de PAK1 dans les OL in vivo augmente l’épaisseur de la gaine de myéline. Dans l’ensemble, nos données indiquent que PAK1 est un régulateur de la dynamique du cytosquelette d’actine dans les OL. Cette nouvelle fonction de PAK1 est dissociée de celle de PAK3 que nous avions caractérisée comme régulateur positif de la différenciation des précurseurs oligodendrocytaires (OPC). PAK1 et PAK3 agissent ainsi de manière distincte et coordonnée pour permettre le développement des OPC et la myélinisation chez le rongeur.

  • Open Access

    Cell-autonomous mitochondrial calcium flux governs oligodendrocyte regeneration

    by Dorien A. Maas, Roxane Bancel-Vega, Lucas R. Baudouin, Philippe Bun, Blandine Manot-Saillet, Chloé Habermacher, Niels Verburg, Filippo Rusconi, Maria Cecilia Angulo

    Oligodendrocyte (OL) lineage cells drive central nervous system remyelination, yet the intrinsic mechanisms that define their regenerative potential remain unclear. We identify spontaneous, cell-autonomous intracellular Ca 2+ signaling as a critical mechanism regulating OL regeneration following demyelination. Longitudinal in vivo imaging and ex vivo recordings reveal that Ca 2+ signaling arises intrinsically within OL lineage cells after demyelination, and occurs independently from neuronal or behavioral activity. Mechanistically, mitochondrial Ca 2+ flux sustains intracellular Ca 2+ signals in oligodendroglia, and its in vivo disruption impairs oligodendrocyte precursor cell (OPC) proliferation, differentiation, and repopulation at the lesion site. Conversely, enhancing oligodendroglial Ca 2+ signaling in vivo using chemogenetics stimulates lineage expansion and differentiation. In primary human OPC cultures, modulation of mitochondrial Ca 2+ flux similarly reduces proliferation, indicating a conserved role for this pathway across species. These findings identify mitochondrial Ca 2+ flux as a central driver of the oligodendroglial regeneration and a potential therapeutic target in demyelinating diseases.

  • Open Access

    Author Correction: Pharmacogenomic screening identifies and repurposes leucovorin and dyclonine as pro-oligodendrogenic compounds in brain repair

    by Jean-Baptiste Huré, Louis Foucault, Litsa Maria Ghayad, Corentine Marie, Nicolas Vachoud, Lucas Baudouin, Rihab Azmani, Natalija Ivljanin, Alvaro Arevalo-Nuevo, Morgane Pigache, et al.

  • Open Access

    Pharmacogenomic screening identifies and repurposes leucovorin and dyclonine as pro-oligodendrogenic compounds in brain repair

    by Jean-Baptiste Huré, Louis Foucault, Litsa Maria Ghayad, Corentine Marie, Nicolas Vachoud, Lucas Baudouin, Rihab Azmani, Natalija Ivljanin, Alvaro Arevalo-Nuevo, Morgane Pigache, et al.

    Oligodendrocytes are critical for CNS myelin formation and are involved in preterm-birth brain injury (PBI) and multiple sclerosis (MS), both of which lack effective treatments. We present a pharmacogenomic approach that identifies compounds with potent pro-oligodendrogenic activity, selected through a scoring strategy (OligoScore) based on their modulation of oligodendrogenic and (re)myelination-related transcriptional programs. Through in vitro neural and oligodendrocyte progenitor cell (OPC) cultures, ex vivo cerebellar explants, and in vivo mouse models of PBI and MS, we identify FDA-approved leucovorin and dyclonine as promising candidates. In a neonatal chronic hypoxia mouse model mimicking PBI, both compounds promote neural progenitor cell proliferation and oligodendroglial fate acquisition, with leucovorin further enhancing differentiation. In an adult MS model of focal de/remyelination, they improve lesion repair by promoting OPC differentiation while preserving the OPC pool. Additionally, they shift microglia from a pro-inflammatory to a pro-regenerative profile and enhance myelin debris clearance. These findings support the repurposing of leucovorin and dyclonine for clinical trials targeting myelin disorders, offering potential therapeutic avenues for PBI and MS.


  • Open Access

    Pharmacogenomic screening identifies and repurposes leucovorin and dyclonine as pro-oligodendrogenic compounds in brain repair

    by Jean-Baptiste Huré, Louis Foucault, Litsa Maria Ghayad, Corentine Marie, Nicolas Vachoud, Lucas Baudouin, Rihab Azmani, Natalija Ivjanin, Alvaro Arevalo-Nuevo, Morgane Pigache, et al.

    Oligodendrocytes are the myelin-forming cells of the central nervous system (CNS), with oligodendroglial pathologies leading to strong disabilities, from early preterm-birth brain injury (PBI) to adult multiple sclerosis (MS). No medication presenting convincing repair capacity in humans has been approved for these pathologies so far. Here, we present a pharmacogenomic approach leading to the identification of small bioactive molecules with a large pro-oligodendrogenic activity, selected through an expert curation scoring strategy ( OligoScore ) of their large impact on transcriptional programs controlling oligodendrogenesis and (re)myelination. We demonstrate the pro-oligodendrogenic activity of these compounds in vitro, using neural and oligodendrocyte progenitor cell (OPC) cultures, as well as ex vivo, using organotypic cerebellar explant cultures. Focusing on the two most promising molecules, i.e. leucovorin and dyclonine, we tested their therapeutic efficacy using a mouse model of neonatal chronic hypoxia, which faithfully mimics aspects of PBI. In this model, both compounds promoted proliferation and oligodendroglial fate acquisition from neural stem/progenitor cells, with leucovorin also promoting their differentiation. We extended these findings to an adult focal de/remyelination mouse MS model, in which both compounds improved lesion repair by promoting OPC differentiation while maintaining the pool of OPCs, and in parallel, by accelerating the transition from pro-inflammatory to pro-regenerative microglial profiles and myelin debris clearance. This study paves the way for clinical trials aimed at repurposing these FDA-approved compounds to treat myelin pathologies such as PBI and MS. Graphical Pharmacogenomic screening identifies and repurposes dyclonine and leucovorin as pro-oligodendrogenic and pro-myelinating compounds. Schematics of the pharmacogenomic approach leading to the identification of small bioactive molecules (compounds) with potential pro-oligodendrogenic activity, followed by the in vitro validation of the top compounds using neural and oligodendrocyte progenitor cell (OPC) cultures as well as organotypic cerebellar explants. The therapeutic efficacy of the top two compounds, leucovorin and dyclonine, both approved by the Food and Drug Administration (FDA), was assessed in vivo using two clinically relevant mouse models of myelin pathologies. In the neonatal hypoxia mouse model, mimicking some aspects of preterm brain injury, both leucovorin and dyclonine promoted neural stem cell (NSC) differentiation into OPCs and OPC proliferation, with leucovorin additionally restoring the density of myelinating OLs found in normoxic conditions. In an adult focal de/remyelination mouse model of multiple sclerosis, both compounds significantly improved lesion repair in adult mice by promoting OPC differentiation while preserving the pool of OPCs, and by accelerating myelin debris clearance and shifting microglia from pro-inflammatory to pro-regenerative profiles.

  • Open Access

    Cover Image, Volume 69, Issue 8

    by Lucas Baudouin, Noémie Adès, Kadia Kanté, Antonny Czarnecki, Corinne Bachelin, Asha Baskaran, Dominique Langui, Aymeric Millécamps, Basile Gurchenkov, Yoan Velut, et al.

  • Co‐culture of exogenous oligodendrocytes with unmyelinated cerebella: Revisiting ex vivo models and new tools to study myelination

    by Lucas Baudouin, Noémie Adès, Kadia Kanté, Antonny Czarnecki, Corinne Bachelin, Asha Baskaran, Dominique Langui, Aymeric Millécamps, Basile Gurchenkov, Yoan Velut, et al.

    Common in vitro models used to study the mechanisms regulating myelination rely on co‐cultures of oligodendrocyte precursor cells (OPCs) and neurons. In such models, myelination occurs in an environment that does not fully reflect cell–cell interactions and environmental cues present in vivo. To avoid these limitations while specifically manipulating oligodendroglial cells, we developed a reliable ex vivo model of myelination by seeding OPCs on cerebellar slices, deprived of their endogenous oligodendrocytes. We showed that exogenous OPCs seeded on unmyelinated cerebella, efficiently differentiate and form compact myelin. Spectral confocal reflectance microscopy and electron microscopy analysis revealed that the density of compacted myelin sheaths highly increases all along the culture. Importantly, we defined the appropriate culture time frame to study OPC differentiation and myelination, using accurate quantification resources we generated. Thus, this model is a powerful tool to study the cellular and molecular mechanisms of OPC differentiation and myelination. Moreover, it is suitable for the development and validation of new therapies for myelin‐related disorders such as multiple sclerosis and psychiatric diseases.


  • The intellectual disability protein PAK3 regulates oligodendrocyte precursor cell differentiation

    by Majistor Raj Luxman Maglorius Renkilaraj, Lucas Baudouin, Claire M. Wells, Mohamed Doulazmi, Rosine Wehrlé, Vidjeacoumary Cannaya, Corinne Bachelin, Jean-Vianney Barnier, Zhengping Jia, Brahim Nait Oumesmar, et al.